Editor in Chief Dr KK Aggarwal, Padma Shri Awardee                                                                               Dated:22 June,2020

Unusual symptoms of Covid-19 on the rise in Kolkata

KOLKATA: Covid-19 cases with “unusual symptoms”, which the union health ministry has spoken about, are on the rise in Kolkata, say city doctors.
The health ministry expanded the Covid symptom list on June 12 to include muscle pain, diarrhoea and loss of taste and smell. A few patients with some of these symptoms, including two employees of a superspeciality hospital and a patient from Bihar, have already been discharged from clinics in Kolkata.
None of them showed the “principal Covid symptom of severe upper respiratory distress”, their doctors said, making the initial diagnosis that much more difficult. One of the three did not even even have fever but all three suffered from diarrhoea for a week; one had lost her sense of smell and another had “minor breathing difficulty” without fever or cold. ....read more

Plasma Therapy: Not a Magic Cure

Reproduced from: India Legal, https://www.indialegallive.com/special-story/plasma-therapy-not-a-magic-cure published June 15, 2020
While the therapy has been touted as a remedy for corona, there can be transfusion reactions or the disease worsening. This includes acute lung injury or acute respiratory distress
A 47-year-old woman, who was the first Covid-19 patient to receive plasma therapy at Sassoon General Hospital in Pune, tested negative for the disease. ICMR has now given permission to many government and private hospitals to use plasma therapy for off-label use in Covid-19 conditions. ....read more

CMAAO Coronavirus Facts and Myth Buster: Headache in COVID

952: Headache as presenting symptom of COVID-19
In a case series published in the journal Headache, Jyotika Singh, DO, Henry Ford Health System, Department of Neurology, Detroit, Michigan, US, and another colleague, describe two cases of women with a history of migraine whose first symptom of COVID-19 was a severe persistent headache.
The first case was that of a 31-year-old female, with a history of episodic migraine. Her migraine attacks typically occur once or twice a month, are unilateral, throbbing, moderate-to-severe in intensity, and associated with photophonophobia and nausea. Her headaches generally last from 2-8 hours with treatment. ....read more

The spiritual prescription "I am sorry"

Two hardest words for a doctor to say: "I’m sorry." Most defence lawyers counsel doctors to not apologize to patients. Their view is that if you say you’re sorry for something, you are implicitly taking some degree of responsibility for whatever has happened. In other words, you are pleading guilty. The complainant’s lawyers may use a doctor’s apology to the maximum extent possible to show the doctor knew what they did was wrong. The usual approach is to deny and defend. But, ....read more

Video of The day

Can RT PCR test be false positive



Healthcare News Monitor
After FabiFlu, Hetero’s antiviral drug Covifor gets DCGI approval to treat Covid-19 patients
Hindustan TimesSohini Sarkar

“In the light of increasing Covid-19 cases in India, the approval of ‘COVIFOR’ (Remdesivir) can prove to be a game-changer given its positive clinical outcomes. Backed by strong backward integration capabilities, we can ensure that the product is immediately made available to patients across the country,” Dr. B Partha Saradhi Reddy, Chairman, Hetero Group of Companies said on the DCGI nod.
The drug Remdesivir has been granted approval by DCGI for the treatment of suspected or laboratory-confirmed cases of Covid-19 in adults and children, hospitalized with severe symptoms of the infectious disease.

Coronavirus Cure: DGCI approves Glenmark to manufacture Favipiravir for COVID-19 treatment; here’s all you need to know

New Delhi | Jagran News Desk: The Drug Controller General of India (DCGI) has approved the Mumbai-based Glenmark Pharmaceuticals to manufacture the anti-viral drug, Favipiravir, to treat the coronavirus patients across the country.
The approval was given after the Glenmark on Saturday informed that their antiviral drug -- Favipiravir -- has shown clinical improvement of up to 88 per cent in mild to moderate COVID-19 cases, including those with co-morbidities. The DCGI had also given Glenmark permission to market the drug in the Indian market, which is expected to be available in the market in the next few days.

8 Hospitals in 15 Hours: A Pregnant Woman’s Crisis in the Pandemic
The NY Times

NEW DELHI — Neelam Kumari Gautam woke up at 5 a.m. with shooting labor pains. Her husband put her gently in the back of a rickshaw and motored with her to a hospital. Then another. Then another. Her pain was so intense she could barely breathe, but none would take her.
“Why are the doctors not taking me in?” she asked her husband, Bijendra Singh, over and over again. “What’s the matter? I will die.” ,Mr. Singh began to panic. He knew what he was up against. As India’s coronavirus crisis has accelerated — India is now reporting more infections a day than any other nation except the United States or Brazil — the country’s already strained and underfunded health care system has begun to buckle.

India Today

On Saturday, a doctor died of the novel coronavirus disease or Covid-19 at Delhi's Rajiv Gandhi Super Speciality Hospital.,2. A day before, a blood bank manager at a private hospital in the city succumbed to the highly infectious ailment. , On June 15, at least 20 AIIMS healthcare workers tested positive for the deadly virus. , On the same day, a doctor working at a mohalla clinic in Delhi died of Covid-19. , On June 3, a nurse in the city lost her life to it.